Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has shared an announcement.
CSL Limited has provided an updated daily notification on its ongoing on-market share buy-back of ordinary fully paid shares, originally launched in August 2025. The company disclosed that it had repurchased a cumulative 6,352,089 shares prior to the latest trading day, and bought back a further 54,887 shares on the previous day, as part of the current capital management program.
The continued execution of the buy-back signals CSL’s active approach to balance sheet optimisation and shareholder returns, potentially supporting earnings per share through a reduced share count. The steady pace of repurchases also underscores management’s confidence in the company’s long-term outlook and may bolster market perception of value in the stock among investors monitoring buy-back activity.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$244.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biopharmaceutical company listed on the ASX, best known for developing and manufacturing vaccines, plasma-derived therapies and other specialty medicines. The group targets serious and rare diseases as well as influenza prevention, and is widely held by institutional and retail investors in the Australian healthcare sector.
YTD Price Performance: -26.76%
Average Trading Volume: 1,459,923
Technical Sentiment Signal: Sell
Current Market Cap: A$60.59B
Learn more about CSL stock on TipRanks’ Stock Analysis page.